OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Neurology is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Prevalence of infratentorial superficial siderosis in a large general population sample from the UK Biobank	122
The deltoid muscle and the pattern of paresis in ALS	117
A role for the Epstein–Barr virus in multiple sclerosis aetiology?	117
Pallidal deep brain stimulation for patients with myoclonus-dystonia without SGCE mutations	108
Richard Caton (1842-1926)	102
CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective	99
Microstructural characterization of multiple sclerosis lesion phenotypes using multiparametric longitudinal analysis	94
Neuromyelitis optica spectrum disorder with a familial Mediterranean fever gene E84K mutation	89
Tacrolimus-induced Parkinsonism	88
Interpretable deep learning survival predictions in sporadic Creutzfeldt–Jakob disease	83
Different patterns of acute saccadic response to levodopa in de novo Parkinson’s disease	71
Reversible cerebral vasoconstriction syndrome after intravenous iron substitution: a case report	65
Brain 18F-FDG PET findings and sequential vestibular testing in SCA27B: a case report	63
Neurological manifestation of HEV infection: still a rare disease entity?	63
The DeMyers: Marian (1922–2012) and William (1924–2008)	61
Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod	61
Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study	60
Hashimoto’s encephalopathy with diffuse leukoencephalopathy: serial MRI and gait analysis	59
Tourette syndrome: effects of acetyl-leucine in two individuals	58
Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies	57
Natalizumab-induced pneumonitis	57
Stroke frequency, associated factors, and clinical features in primary systemic vasculitis: a multicentric observational study	56
Correction to: Synergistic effects of vagus nerve stimulation and antiseizure medication	55
Correction to: Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study	55
Long-term outcome after decompressive hemicraniectomy for malignant middle cerebral artery infarction	55

Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy	54
A decision aid is not the quick fix for improving shared decision-making in advanced Parkinson’s disease: results of a mixed methods feasibility study	53
Exploring epigenetic modifications as potential biomarkers and therapeutic targets in amyotrophic lateral sclerosis	51
Increased aneurysm wall permeability colocalized with low wall shear stress in unruptured saccular intracranial aneurysm	49
Does visuospatial motion perception correlate with coexisting movement disorders in Parkinson’s disease?	49
International survey on the implementation of the European and American guidelines on disorders of consciousness	48
Acute symptomatic seizures and hippocampal sclerosis: the major contributor for post-stroke epilepsy?	48
A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution	48
Dystonia management across Europe within ERN-RND: current state and future challenges	48
Phenotype-driven reanalysis reveals five novel pathogenic variants in 40 exome-negative families with Charcot–Marie–Tooth Disease	47
Keeping an eye on Parkinson’s disease: color vision and outer retinal thickness as simple and non-invasive biomarkers	47
Improving conscientiousness through a smartphone app and telecoaching intervention: insights from multiple sclerosis and healthy aging samples	45
Longitudinal predictors of health-related quality of life in isolated dystonia	45
Eye tracking identifies biomarkers in α-synucleinopathies versus progressive supranuclear palsy	45
Assessment of cognitive function, structural brain changes and fatigue 6 months after treatment of neuroborreliosis	44
Restless legs syndrome in Parkinson’s disease: epidemiology, pathogenetic overlaps, and clinical management	44
Analysis of C9orf72 repeat length in progressive supranuclear palsy, corticobasal syndrome, corticobasal degeneration, and atypical parkinsonism	44
Tau levels in platelets isolated from Huntington’s disease patients serve as a biomarker of disease severity	43